Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IQCJ-SCHIP1 readthrough antisense RNA 1 (abbreviated as IQCJ-SCHIP1-AS1) is a long non-coding RNA (lncRNA) classified as an antisense transcript located on chromosome 3. It does not encode a protein and functions primarily at the RNA level. Its expression is downregulated in colorectal cancer tissues and its reduced levels are associated with advanced tumor characteristics and poor prognosis. IQCJ-SCHIP1-AS1 appears to suppress tumor growth by regulating cell cycle, proliferation, and apoptosis pathways. While it is not a traditional drug target (receptor, enzyme, transporter), it may serve as a novel prognostic biomarker in cancer, particularly colorectal cancer. There are no known drug interactions or direct therapeutic actions identified for this lncRNA to date. Note: IQCJ-SCHIP1-AS1 should not be confused with the protein-coding readthrough transcript IQCJ-SCHIP1 (sometimes with similar name but distinct function), nor does it encode a receptor or protein itself; it acts as a long non-coding RNA modulator of gene expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IQCJ-SCHIP1 readthrough antisense RNA 1 (IQCJ-SCHIP1-AS1).